Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. (ADIL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ADIL · as of Sep 30, 2025
Ownership Breakdown
16
Institutional Holders
$214,070
Total Inst. Value
▲ $143,917 vs Q2
959,644
Shares Outstanding
freeFloat 99.51%
608,084
13F Shares Held
▲ 373,379 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ADIL largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 164.1K | 74.03% | 74.03% | $58.02M | Nov 12, 2025 | ▲ 95.3K |
VANGUARD GROUP INC pharmaceutical preparations | 156.0K | 70.37% | 70.37% | $55.23M | Nov 7, 2025 | ▲ 142.9K |
CITADEL ADVISORS LLC pharmaceutical preparations | 143.8K | 64.85% | 64.85% | $50.83M | Nov 14, 2025 | NEW |
MANCHESTER CAPITAL MANAGEMENT LLC pharmaceutical preparations | 48.1K | 21.69% | 21.69% | $17.00M | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 27.8K | 12.53% | 12.53% | $9.82M | Nov 12, 2025 | — held |
UBS GROUP AG pharmaceutical preparations | 18.8K | 8.46% | 8.46% | $6.62M | Nov 13, 2025 | ▲ 6.4K |
TWO SIGMA SECURITIES, LLC pharmaceutical preparations | 12.8K | 5.79% | 5.79% | $4.54M | Nov 14, 2025 | NEW |
JANE STREET GROUP, LLC pharmaceutical preparations | 12.3K | 5.57% | 5.57% | $4.36M | Nov 14, 2025 | ▼ 12.5K |
HRT FINANCIAL LP pharmaceutical preparations | 11.2K | 5.05% | 5.05% | $3.00M | Nov 14, 2025 | ▼ 7.9K |
PRIVATE MANAGEMENT GROUP INC pharmaceutical preparations | 10.0K | 4.51% | 4.51% | $3.54M | Nov 13, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
5
Increased
+244.7K shares3
New Positions
first time holders3
Decreased
−20.5K shares3
Sold Out
fully exitedNet shares change (top 50)
+224.2K
+244.7K / −20.5K
Net new holders
+2
3 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ADIL insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Goodman Tony Chief Operating Officer | Apr 7, 2026 | Award | 26,510 | — | — | 26.5K | Form 4 ↗ |
Anderson J. Kermit director | Apr 7, 2026 | Award | 9,185 | $1.64 | $15.1K | 9.2K | Form 4 ↗ |
Schuyler Kevin director | Apr 7, 2026 | Award | 9,185 | — | — | 9.2K | Form 4 ↗ |
Shah Vinay Chief Financial Officer | Apr 7, 2026 | Award | 17,325 | — | — | 17.3K | Form 4 ↗ |
Gilliland Robertson H. director | Apr 7, 2026 | Award | 9,185 | — | — | 9.2K | Form 4 ↗ |
Claiborne Cary J Chief Executive Officer | Apr 7, 2026 | Award | 37,985 | — | — | 40.4K | Form 4 ↗ |
Gilliland Robertson H. director | May 29, 2025 | Award | 28,000 | $0.69 | $19.3K | 28.0K | Form 4 ↗ |
Newman James W. Jr. director | May 29, 2025 | Award | 28,000 | $0.69 | $19.3K | 28.0K | Form 4 ↗ |
Shah Vinay Chief Financial Officer | May 29, 2025 | Award | 9,000 | $0.69 | $6.2K | 9.0K | Form 4 ↗ |
Schuyler Kevin director | May 29, 2025 | Award | 28,000 | $0.69 | $19.3K | 28.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Adial Pharmaceuticals, Inc. (ADIL) is primarily owned by institutional investors, who hold approximately 63.4% of total shares outstanding. Company insiders own approximately 0.49%, while retail and public investors account for the remaining 36.14%.
The largest institutional shareholder of Adial Pharmaceuticals, Inc. is GEODE CAPITAL MANAGEMENT, LLC, holding approximately 164,127 shares — equal to 74.03% of outstanding shares — as of September 30, 2025.
A total of 16 institutional investors currently hold ADIL stock, with a combined institutional value of approximately $214,070 as of the most recent 13F filing period.
Frequently asked questions
ADIL ownershipAdial Pharmaceuticals, Inc. (ADIL) is primarily owned by institutional investors, who hold approximately 63.4% of shares. The largest shareholder is GEODE CAPITAL MANAGEMENT, LLC with a 74.03% stake. Company insiders hold 0.49%. Data sourced from SEC Form 13F as of September 30, 2025.